新闻档案

通过选择所需的新闻类型,可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见,某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处,请以PDF版本为准。

新闻类型
演示文稿
监管信息公告
新闻主题
创新平台
商业平台
监管通知
集团
1
2345678910
找到相关结果: 452
伦敦:2020年3月31日(星期二):和黄中国医药科技有限公司(简称 “和黄医药” 或 “Chi-Med”)(纳斯达克/AIM: HCM)启动了一项HMPL-453治疗晚期恶性间皮瘤患者的II期临床试验。HMPL-453是一
阅读更多
London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee
阅读更多
London: Monday, March 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under the Long Term Incen
阅读更多
注:本文件的中文本为翻译稿,仅供参考用。本文件的英文及中文版本如有歧义,概以英文版本为准。完整版本(仅备英文版)请参阅此处。   伦敦,2020年3月3日,星期二: 和黄中国
阅读更多
London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd
阅读更多
新闻稿   伦敦,2020年2月10日,星期一:  和黄中国医药科技有限公司(简称 “和黄医药” 或 “Chi-Med”)(AIM/Nasdaq: HCM) 今日公布CALYPSO II期临床研究中探索沃利替尼/Imfinzi®(durvalumab / 度
阅读更多
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, February 6, 2020: Hutchiso
阅读更多
The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem
阅读更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
阅读更多
本公告全部或部分内容的发布、刊发或派发,不得于或向或从任何视此等举措属违反当地有关法律的司法管辖区进行。(本文件的中文本为翻译稿,仅供参考用。本文件的英文及中文版本
阅读更多
本公告全部或部分内容的发布、刊发或派发,不得于或向或从任何视此等举措属违反当地有关法律的司法管辖区进行。 (本文件的中文本为翻译稿,仅供参考用。本文件的英文及中文版本如
阅读更多
伦敦,2020年1月20日,星期一:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”)(AIM/纳斯达克:HCM)今日宣布索凡替尼以晚期胰腺神经内分泌瘤为适应症的III 期关键性研究SANET-p
阅读更多
伦敦,2020年1月13日,星期一:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”)(AIM/纳斯达克:HCM)在中国启动了一项索凡替尼联合拓益(特瑞普利单抗)治疗晚期实体瘤患者的
阅读更多
新闻稿 伦敦:2020年1月6日(星期一):和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”)(AIM/纳斯达克:HCM)今日宣布,首席执行官贺隽(Christian Hogg)将出席于美国旧金山举办
阅读更多
London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2019, the issued share capital of Chi-Med consisted of 666,906,450 ordinary shares of US$0.10 ea
阅读更多
London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited
阅读更多
新闻稿 伦敦:2019年12月20日,星期五:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”) (AIM/Nasdaq: HCM) 今天宣布中国国家药品监督管理局(“国家药监局”)药品审评中心将
阅读更多
London: Thursday, December 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on December 11, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General
阅读更多
London: Friday, November 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 29, 2019, the issued share capital of Chi-Med consisted of 666,886,450 ordinary shares of US$0.10 eac
阅读更多
伦敦:2019年11月28日,星期四:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”)(AIM/Nasdaq: HCM)今天宣布其用于治疗晚期结直肠癌的国家1类靶向抗癌药物爱优特®(呋喹替尼胶
阅读更多
伦敦:2019年11月25日,星期一:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”) (AIM/Nasdaq: HCM) 今天宣布索凡替尼获美国食品药品监督管理局(“ FDA”)授予孤儿药资格用于
阅读更多
伦敦:2019年11月23日,星期六:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med ”) (AIM/Nasdaq: HCM) 将于2019年11月22日至24日在新加坡举行的第五届欧洲肿瘤内科学会(“ESMO ”)
阅读更多
伦敦:2019年11月11日,星期一:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”)(AIM/Nasdaq: HCM)今日宣布,中国国家药品监督管理局(NMPA)已受理索凡替尼(surufatinib)用于治疗
阅读更多
伦敦,2019年10月17 日,星期四 :和黄中国医药科技有限公司 (简称“和黄医药”或“Chi-Med”) (AIM/纳斯达克: HCM)今日重点介绍于美国癌症研究协会的期刊《癌症发现(Cancer Discovery)》[1] 发表
阅读更多
London: Thursday, October 10, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Me
阅读更多
中国苏州及英国伦敦,2019年10月10日,星期四:信达生物制药(“信达生物“)(香港联交所股票代码:01801)与和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”)(AIM/纳斯达
阅读更多
伦敦,2019年10月4日,星期五:和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”) (AIM/Nasdaq:HCM)启动了一项HMPL-523治疗复发性或难治性淋巴瘤患者的国际I/Ib期临床试验。HMPL-523是
阅读更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
阅读更多
本新闻稿全部或部分内容的发布、刊发或派发,不得于或向或从任何视此等举措属违反当地有关法律的司法管辖区进行。 (本文件的中文本为翻译稿,仅供参考用。本文件的英文及中文版本
阅读更多
本新闻稿全部或部分内容的发布、刊发或派发,不得于或向或从任何视此等举措属违反当地有关法律的司法管辖区进行。 (本文件的中文本为翻译稿,仅供参考用。本文件的英文及中文版
阅读更多
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e
阅读更多
– 索凡替尼在III期临床试验SANET-ep中达到了主要终点,帮助降低非胰腺神经内分泌瘤(“NET”)患者的疾病进展或死亡风险达67% – –目前正筹备计划于2019年底前提交索凡替尼用于非胰腺神
阅读更多
—即将发表关于索凡替尼治疗非胰腺神经内分泌肿瘤患者的SANET-ep III期临床试验积极结果的最新摘要— —将于9月30日(星期一)联同试验主要研究者举行电话会议和网络音频直播,共同解
阅读更多
伦敦:2019年9月18日(星期三):和黄中国医药科技有限公司(简称“和黄医药”或“Chi-Med”) (AIM/Nasdaq:HCM) 将于2019年9月18-22日在中国厦门举行的第22届全国临床肿瘤学大会暨2019年CSCO学
阅读更多
伦敦:2019年9月3日(星期二):和黄中国医药科技有限公司(简称和黄医药“Chi-Med”)(AIM/纳斯达克:HCM)今日宣布,首席执行官Christian Hogg将于2019年9月11日星期三上午9点55分(美国东部时间)
阅读更多
伦敦,2019年9月3日(星期二):和黄中国医药科技有限公司 (简称和黄医药“Chi-Med”) (AIM/Nasdaq:HCM)启动了一项HMPL-689治疗复发性或难治性淋巴瘤患者的国际I/Ib期临床试验。HMPL-689是一种作用
阅读更多
London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w
阅读更多
伦敦 ,2019年8月23日 (星期五):和黄中国医药科技有限公司 (简称“和黄医药”或“Chi-Med”) (AIM/Nasdaq: HCM) 在中国启动了一项HMPL-523治疗免疫性血小板减少性紫癜(“ITP”)患者的I期临床试验。H
阅读更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
阅读更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
阅读更多
伦敦:2019年7月30日(星期二): 和黄中国医药科技有限公司(Chi-Med)(AIM /纳斯达克股票代码: HCM)今天公布截至2019年6月30日的未经审核财务数据,并公布了关键临床项目的最新进展。重点包
阅读更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
阅读更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
阅读更多
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
阅读更多
London: Friday, June 28, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limite
阅读更多
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“
阅读更多
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 27, 2019: Hutchison China MediTech Limited (“
阅读更多
香港:2019 年6 月14 日,周五:和黄中国医药科技有限公司(Chi-Med)(AIM/Nasdaq: HCM)今日宣布索凡替尼以晚期非胰腺神经内分泌瘤为适应症的III 期关键性研究SANET-ep 预设的中期分析已由该研
阅读更多
London: Wednesday, June 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordinary shares, par value
阅读更多
London: Thursday, June 6, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connec
阅读更多